Antibody-drug Conjugate Information
General Information of This Antibody-drug Conjugate (ADC)
| ADC ID |
DRG0GCCJJ
|
|||||
|---|---|---|---|---|---|---|
| ADC Name |
LM-302
|
|||||
| Synonyms |
LM 302; LM-302; TPX-4589; BMS-986476
Click to Show/Hide
|
|||||
| Organization |
LaNova Medicines Ltd.; Turning Point Therapeutics, Inc.
|
|||||
| Drug Status |
Phase 2
|
|||||
| Indication |
In total 2 Indication(s)
Gastroesophageal cancer [ICD11:2B71]
Phase 2
Solid tumors [ICD11:2A00-2A0Z|2B50-2F9Z]
Phase 2
|
|||||
| Structure |
|
|||||
| Antibody Name |
Anti-CLDN18.2 mAb
|
Antibody Info | ||||
| Antigen Name |
Claudin-18.2 (CLDN18.2)
|
Antigen Info | ||||
| Payload Name |
Monomethyl auristatin E
|
Payload Info | ||||
| Therapeutic Target |
Microtubule (MT)
|
Target Info | ||||
| Linker Name |
Undisclosed
|
|||||
| Conjugate Type |
Random conjugation through reduced inter-chain cysteines.
|
|||||
| Special Approval(s) |
Orphan drug(FDA)
|
|||||
| Puchem SID | ||||||
If you find any error in data or bug in web service, please kindly report it to Dr. Shen et al.